Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
obrixtamig + pumitamig
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Obrixtamig + pumitamig is an investigational combination regimen being evaluated for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The combination consists of obrixtamig (BI 764532), Boehringer Ingelheim's bispecific DLL3/CD3 T-cell engager, and pumitamig (BNT327/BMS-986545), a PD-L1/VEGF-A bispecific antibody jointly developed by BioNTech and Bristol Myers Squibb. Obrixtamig redirects CD3-positive T-cells to kill tumor cells expressing delta-like ligand 3 (DLL3), a protein highly expressed in SCLC and other neuroendocrine tumors. Pumitamig simultaneously blocks programmed death-ligand 1 (PD-L1) to restore T-cell activity and neutralizes vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis and alleviate the immunosuppressive tumor microenvironment. Boehringer Ingelheim and BioNTech are evaluating the safety, tolerability, and efficacy of this dual-bispecific combination in a Phase Ib/II clinical trial (NCT07843940, Dareon-Rosetta35) for patients with previously treated or treatment-naive ES-SCLC.
- Other names
- BI 764532 + pumitamigobrixtamig + BMS-986545obrixtamig + BNT327pumitamig + obrixtamig
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)VEGFR (VEGFR family)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on obrixtamig + pumitamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on obrixtamig + pumitamig.